Open AccessReal-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer
Author(s) -
Whitney Rhodes,
Richard W DeClue,
Neil A. Accortt,
Ran Jin,
Darcie Sandschafer,
Debra Wertz,
Karan Patel
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0588
Subject(s) - bevacizumab , medicine , biosimilar , colorectal cancer , oncology , cancer , chemotherapy
Aim: Evaluated real world use of bevacizumab-awwb (MVASI ® ), a bevacizumab biosimilar, for treating metastatic colorectal cancer (mCRC). Materials & methods: Adult mCRC patients who received bevacizumab-awwb during the first year after market availability were identified from the ConcertAI oncology dataset. Results: Of 304 patients, 47% initiated bevacizumab-awwb as reference product (RP) naive patients and 53% received bevacizumab-awwb with prior exposure to RP. Overall, 78% received bevacizumab-awwb as first-line therapy; the proportion was higher (91%) in RP-naive patients. Among RP-experienced patients, 83% were transitioned from RP to bevacizumab-awwb in the same line without disease progression; of those, the majority (83%) were transitioned within 28 days. Conclusion: Early evidence from US oncology practices suggests clinical adoption of bevacizumab-awwb in treating mCRC patients.